Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry
| العنوان: | Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry |
|---|---|
| المؤلفون: | S. de la Fuente, D. Ruiz-Vílchez, Alejandro Escudero-Contreras, Eduardo Collantes-Estevez, J. Calvo-Gutiérez, M.C. Castro-Villegas, Pilar Font, Miguel A. Casado, Manuel Romero-Gómez, M. Cárdenas, J. R. Del Prado |
| المصدر: | Rheumatology International. 36:231-241 |
| بيانات النشر: | Springer Science and Business Media LLC, 2015. |
| سنة النشر: | 2015 |
| مصطلحات موضوعية: | Adult, Male, musculoskeletal diseases, medicine.medical_specialty, Time Factors, Cost effectiveness, Cost-Benefit Analysis, Immunology, Arthritis, Drug Costs, Etanercept, Arthritis, Rheumatoid, Biological drugs, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Cost Savings, immune system diseases, Internal medicine, medicine, Adalimumab, Humans, Immunology and Allergy, Registries, 030212 general & internal medicine, skin and connective tissue diseases, Aged, 030203 arthritis & rheumatology, business.industry, Remission Induction, Middle Aged, medicine.disease, Infliximab, Surgery, stomatognathic diseases, Models, Economic, Treatment Outcome, Spain, Antirheumatic Agents, Rheumatoid arthritis, Female, business, medicine.drug |
| الوصف: | Biological drugs have proven efficacy and effectiveness in treatment of rheumatoid arthritis (RA), although none has been shown to be superior. Few studies have evaluated the cost-effectiveness of biological drugs in real-life clinical conditions. The objective of this study was to compare the cost-effectiveness of infliximab, etanercept and adalimumab in achieving clinical remission (DAS28 < 2.6) when used as initial biological therapy. Patients were diagnosed with RA who began treatment with infliximab, etanercept or adalimumab in the Reina Sofia Hospital (Cordoba, Spain) between January 1, 2007, and December 31, 2012. Effectiveness was measured as the percentage of patients who achieved clinical remission after 2 years. The cost analysis considered the use of direct health resources (perspective of the healthcare system). Cost-effectiveness was calculated by dividing the total mean cost of each treatment by the percentage of patients who achieved remission. One hundred and thirty patients were included: 55 with infliximab, 44 with adalimumab and 31 with etanercept. After 2 years, 45.2 % of patients with adalimumab achieved clinical remission, versus 29.1 % with infliximab (p = 0.133) and 22.7 % with etanercept (p = 0.040), with no differences between etanercept and infliximab (p = 0.475). The average total cost at 2 years was €29,858, €25,329 and €23,309 for adalimumab, infliximab and etanercept, respectively, while the mean cost (95 %CI) to achieve remission was €66,057 (48,038–84,076), €87,040 (78,496–95,584) and €102,683 (94,559–110,807), respectively. Adalimumab was more efficient than etanercept (p < 0.001) and infliximab (p = 0.026), with no differences between etanercept and infliximab (p = 0.086). Adalimumab was the most cost-effective treatment in achieving clinical remission in real-life clinical conditions in RA patients during the study period. |
| تدمد: | 1437-160X 0172-8172 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::491589869f3e4fe071b8e1286e68e9f1Test https://doi.org/10.1007/s00296-015-3374-2Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....491589869f3e4fe071b8e1286e68e9f1 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1437160X 01728172 |
|---|